{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:33:13Z","timestamp":1751369593212,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s12325-022-02102-8","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T10:10:44Z","timestamp":1653559844000},"page":"3316-3333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["XaMINA: A Real-World, Prospective, Observational Study of Treatment-Na\u00efve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia"],"prefix":"10.1007","volume":"39","author":[{"given":"Ping-Yen","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eue-Keun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen-Yuan","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Myung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Keun","family":"On","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Weon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyung-Wook","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Gu","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsueh-Wei","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon-Hyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The XaMINA Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"2102_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000343667","volume":"40","author":"NE Andrew","year":"2013","unstructured":"Andrew NE, Thrift AG, Cadilhac DA. The prevalence, impact and economic implications of atrial fibrillation in stroke: what progress has been made? Neuroepidemiology. 2013;40:227\u201339. https:\/\/doi.org\/10.1159\/000343667.","journal-title":"Neuroepidemiology"},{"key":"2102_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccl.2015.12.002","volume":"34","author":"F Pistoia","year":"2016","unstructured":"Pistoia F, Sacco S, Tiseo C, et al. The epidemiology of atrial fibrillation and stroke. Cardiol Clin. 2016;34:255\u201368. https:\/\/doi.org\/10.1016\/j.ccl.2015.12.002.","journal-title":"Cardiol Clin"},{"key":"2102_CR3","doi-asserted-by":"publisher","unstructured":"Chiang CE, Wang KL, Lin SJ. Asian strategy for stroke prevention in atrial fibrillation. Europace. 2015;17 Suppl 2:ii31\u20139. https:\/\/doi.org\/10.1093\/europace\/euv231.","DOI":"10.1093\/europace\/euv231"},{"key":"2102_CR4","doi-asserted-by":"publisher","unstructured":"Zirlik A, Bode C. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis. 2017;43:365\u201379. https:\/\/doi.org\/10.1007\/s11239-016-1446-0.","DOI":"10.1007\/s11239-016-1446-0"},{"key":"2102_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med"},{"key":"2102_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med"},{"key":"2102_CR7","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"key":"2102_CR8","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1310907.","journal-title":"N Engl J Med"},{"key":"2102_CR9","unstructured":"Bayer HealthCare Manufacturing Srl. Xarelto\u00ae (rivaroxaban) SOUTH KOREA - Summary of Product Characteristics. 2020. https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetail?itemSeq=200902650. Accessed 18 May 2021."},{"key":"2102_CR10","unstructured":"Bayer AG. Xarelto\u00ae (rivaroxaban) TAIWAN - Summary of Product Characteristics. 2019. https:\/\/info.fda.gov.tw\/MLMS\/H0001D3.aspx?LicId=02025648. Accessed 18 May 2021."},{"key":"2102_CR11","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","volume":"37","author":"AJ Camm","year":"2016","unstructured":"Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37:1145\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehv466.","journal-title":"Eur Heart J"},{"key":"2102_CR12","doi-asserted-by":"crossref","unstructured":"Lauffenburger JC, Farley JF, Gehi AK, et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015;4:e001798.","DOI":"10.1161\/JAHA.115.001798"},{"key":"2102_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/STROKEAHA.117.018395","volume":"49","author":"M Proietti","year":"2018","unstructured":"Proietti M, Romanazzi I, Romiti GF, et al. Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2018;49:98\u2013106. https:\/\/doi.org\/10.1161\/STROKEAHA.117.018395.","journal-title":"Stroke"},{"key":"2102_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/ehjcvp\/pvz072","volume":"7","author":"HF Lee","year":"2021","unstructured":"Lee HF, See LC, Li PR, et al. Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease. Eur Heart J Cardiovasc Pharmacotherap. 2021;7:50\u20138. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz072.","journal-title":"Eur Heart J Cardiovasc Pharmacotherap"},{"key":"2102_CR15","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1161\/STROKEAHA.117.018773","volume":"48","author":"MJ Cha","year":"2017","unstructured":"Cha MJ, Choi EK, Han KD, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation. Stroke. 2017;48:3040\u20138. https:\/\/doi.org\/10.1161\/STROKEAHA.117.018773.","journal-title":"Stroke"},{"key":"2102_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.chest.2019.04.108","volume":"156","author":"YH Chan","year":"2019","unstructured":"Chan YH, Lee HF, See LC, et al. Effectiveness and safety of four direct oral anticoagulants in Asian patients with nonvalvular atrial fibrillation. Chest. 2019;156:529\u201343. https:\/\/doi.org\/10.1016\/j.chest.2019.04.108.","journal-title":"Chest"},{"key":"2102_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008150","volume":"7","author":"YH Chan","year":"2018","unstructured":"Chan YH, See LC, Tu HT, et al. Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation. J Am Heart Assoc. 2018;7: e008150. https:\/\/doi.org\/10.1161\/JAHA.117.008150.","journal-title":"J Am Heart Assoc"},{"key":"2102_CR18","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jacc.2018.05.066","volume":"72","author":"SR Lee","year":"2018","unstructured":"Lee SR, Choi EK, Han KD, et al. Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety. J Am Coll Cardiol. 2018;72:838\u201353. https:\/\/doi.org\/10.1016\/j.jacc.2018.05.066.","journal-title":"J Am Coll Cardiol"},{"key":"2102_CR19","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1161\/STROKEAHA.118.024210","volume":"50","author":"SR Lee","year":"2019","unstructured":"Lee SR, Choi EK, Han KD, et al. Optimal rivaroxaban dose in Asian patients with atrial fibrillation and normal or mildly impaired renal function. Stroke. 2019;50:1140\u20138. https:\/\/doi.org\/10.1161\/STROKEAHA.118.024210.","journal-title":"Stroke"},{"key":"2102_CR20","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1161\/STROKEAHA.119.025536","volume":"50","author":"SR Lee","year":"2019","unstructured":"Lee SR, Choi EK, Kwon S, et al. Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation. Stroke. 2019;50:2245\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.119.025536.","journal-title":"Stroke"},{"key":"2102_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1161\/STROKEAHA.119.028030","volume":"51","author":"SR Lee","year":"2020","unstructured":"Lee SR, Choi EK, Kwon S, et al. Oral anticoagulation in Asian patients with atrial fibrillation and a history of intracranial hemorrhage. Stroke. 2020;51:416\u201323. https:\/\/doi.org\/10.1161\/STROKEAHA.119.028030.","journal-title":"Stroke"},{"key":"2102_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jacc.2018.04.084","volume":"72","author":"YC Lin","year":"2018","unstructured":"Lin YC, Chien SC, Hsieh YC, et al. Effectiveness and safety of standard- and low-dose rivaroxaban in Asians with atrial fibrillation. J Am Coll Cardiol. 2018;72:477\u201385. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.084.","journal-title":"J Am Coll Cardiol"},{"key":"2102_CR23","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.3390\/jcm8122228","volume":"8","author":"J Park","year":"2019","unstructured":"Park J, Lee SR, Choi EK, et al. Effectiveness and safety of direct oral anticoagulant for secondary prevention in Asians with atrial fibrillation. J Clin Med. 2019;8:2228. https:\/\/doi.org\/10.3390\/jcm8122228.","journal-title":"J Clin Med"},{"key":"2102_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.6424","volume":"3","author":"CT Tsai","year":"2020","unstructured":"Tsai CT, Liao JN, Chiang CE, et al. Association of ischemic stroke, major bleeding, and other adverse events with warfarin use vs non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation with a history of intracranial hemorrhage. JAMA Netw Open. 2020;3: e206424. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.6424.","journal-title":"JAMA Netw Open"},{"key":"2102_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijcard.2018.03.063","volume":"261","author":"HF Lee","year":"2018","unstructured":"Lee HF, Chan YH, Tu HT, et al. The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation. Int J Cardiol. 2018;261:78\u201383. https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.063.","journal-title":"Int J Cardiol"},{"key":"2102_CR26","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.jacc.2016.06.062","volume":"68","author":"YH Chan","year":"2016","unstructured":"Chan YH, Kuo CT, Yeh YH, et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2016;68:1389\u2013401. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.062.","journal-title":"J Am Coll Cardiol"},{"key":"2102_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jacc.2018.04.058","volume":"72","author":"P Kirchhof","year":"2018","unstructured":"Kirchhof P, Radaideh G, Kim YH, et al. Global prospective safety analysis of rivaroxaban. J Am Coll Cardiol. 2018;72:141\u201353. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.058.","journal-title":"J Am Coll Cardiol"},{"key":"2102_CR28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrcardio.2014.22","volume":"11","author":"I Sabir","year":"2014","unstructured":"Sabir I, Khavandi K, Brownrigg J, et al. Oral anticoagulants for Asian patients with atrial fibrillation. Nat Rev Cardiol. 2014;11:290\u2013303.","journal-title":"Nat Rev Cardiol"},{"key":"2102_CR29","doi-asserted-by":"crossref","unstructured":"Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation \u2013 the J-ROCKET AF study. Circ J. 2012;76:2104\u201311.","DOI":"10.1253\/circj.CJ-12-0454"},{"key":"2102_CR30","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/STROKEAHA.113.002968","volume":"45","author":"KS Wong","year":"2014","unstructured":"Wong KS, Hu DY, Oomman A, et al. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke. 2014;45:1739\u201347.","journal-title":"Stroke"},{"key":"2102_CR31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/joa3.12073","volume":"34","author":"YH Kim","year":"2018","unstructured":"Kim YH, Shim J, Tsai CT, et al. XANAP: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia. J Arrhythm. 2018;34:418\u201327. https:\/\/doi.org\/10.1002\/joa3.12073.","journal-title":"J Arrhythm"},{"key":"2102_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2147\/VHRM.S63298","volume":"10","author":"AJ Camm","year":"2014","unstructured":"Camm AJ, Amarenco P, Haas S, et al. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vasc Health Risk Manag. 2014;10:425\u201334. https:\/\/doi.org\/10.2147\/VHRM.S63298.","journal-title":"Vasc Health Risk Manag"},{"key":"2102_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ehj.2018.09.002","volume":"70","author":"CAA Martinez","year":"2018","unstructured":"Martinez CAA, Lanas F, Radaideh G, et al. XANTUS-EL: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. Egypt Heart J. 2018;70:307\u201313. https:\/\/doi.org\/10.1016\/j.ehj.2018.09.002.","journal-title":"Egypt Heart J"},{"key":"2102_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jjcc.2019.01.001","volume":"74","author":"T Ikeda","year":"2019","unstructured":"Ikeda T, Ogawa S, Kitazono T, et al. Real-world outcomes of the Xarelto post-authorization safety & effectiveness study in Japanese patients with atrial fibrillation (XAPASS). J Cardiol. 2019;74:60\u20136. https:\/\/doi.org\/10.1016\/j.jjcc.2019.01.001.","journal-title":"J Cardiol"},{"key":"2102_CR35","doi-asserted-by":"crossref","unstructured":"Hori M, Connolly SJ, Ezekowitz MD, et al. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation \u2013 sub-analysis in Japanese population in RE-LY trial. Circ J. 2011;75:800\u20135.","DOI":"10.1253\/circj.CJ-11-0191"},{"key":"2102_CR36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ahj.2014.06.005","volume":"168","author":"S Goto","year":"2014","unstructured":"Goto S, Zhu J, Liu L, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in atrial fibrillation (ARISTOTLE) trial. Am Heart J. 2014;168:303\u20139.","journal-title":"Am Heart J"},{"key":"2102_CR37","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1253\/circj.CJ-15-1082","volume":"80","author":"T Yamashita","year":"2016","unstructured":"Yamashita T, Koretsune Y, Yang Y, et al. Edoxaban versus warfarin in East Asian patients with atrial fibrillation - an ENGAGE AF-TIMI 48 subanalysis. Circ J. 2016;80:860\u20139. https:\/\/doi.org\/10.1253\/circj.CJ-15-1082.","journal-title":"Circ J"},{"key":"2102_CR38","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1161\/STROKEAHA.118.024264","volume":"50","author":"SR Lee","year":"2019","unstructured":"Lee SR, Choi EK, Han KD, et al. Non-vitamin K antagonist oral anticoagulants in Asian patients with supranormal renal function. Stroke. 2019;50:1480\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.118.024264.","journal-title":"Stroke"},{"key":"2102_CR39","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.4070\/kcj.2018.0339","volume":"48","author":"B Joung","year":"2018","unstructured":"Joung B, Lee JM, Lee KH, et al. 2018 Korean guideline of atrial fibrillation management. Korean Circ J. 2018;48:1033\u201380. https:\/\/doi.org\/10.4070\/kcj.2018.0339.","journal-title":"Korean Circ J"},{"key":"2102_CR40","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jfma.2016.10.005","volume":"115","author":"CE Chiang","year":"2016","unstructured":"Chiang CE, Wu TJ, Ueng KC, et al. 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formos Med Assoc. 2016;115:893\u2013952. https:\/\/doi.org\/10.1016\/j.jfma.2016.10.005.","journal-title":"J Formos Med Assoc"},{"key":"2102_CR41","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J"},{"key":"2102_CR42","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","volume":"159","author":"ROCKET AF Study Investigators","year":"2010","unstructured":"ROCKET AF Study Investigators. Rivaroxaban - once-daily, oral, direct Factor Xa inhibition - compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340\u20137.","journal-title":"Am Heart J"},{"key":"2102_CR43","doi-asserted-by":"crossref","unstructured":"Hecker J, Marten S, Keller L, et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2016;115:939\u201349.","DOI":"10.1160\/TH15-10-0840"},{"key":"2102_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11239-017-1519-8","volume":"44","author":"S Helmert","year":"2017","unstructured":"Helmert S, Marten S, Mizera H, et al. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry. J Thromb Thrombolysis. 2017;44:169\u201378. https:\/\/doi.org\/10.1007\/s11239-017-1519-8.","journal-title":"J Thromb Thrombolysis"},{"key":"2102_CR45","doi-asserted-by":"crossref","unstructured":"Beyer-Westendorf J, Ebertz F, F\u00f6rster K, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2015;113:1247\u201357.","DOI":"10.1160\/TH14-11-0954"},{"key":"2102_CR46","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014177","volume":"9","author":"HT Yu","year":"2020","unstructured":"Yu HT, Yang PS, Jang E, et al. Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation. J Am Heart Assoc. 2020;9: e014177. https:\/\/doi.org\/10.1161\/JAHA.119.014177.","journal-title":"J Am Heart Assoc"},{"key":"2102_CR47","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1038\/s41598-020-58665-5","volume":"10","author":"KN Lee","year":"2020","unstructured":"Lee KN, Choi JI, Boo KY, et al. Effectiveness and safety of off-label dosing of non-vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients. Sci Rep. 2020;10:1801. https:\/\/doi.org\/10.1038\/s41598-020-58665-5.","journal-title":"Sci Rep"},{"key":"2102_CR48","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","volume":"68","author":"BA Steinberg","year":"2016","unstructured":"Steinberg BA, Shrader P, Thomas L, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68:2597\u2013604. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.966.","journal-title":"J Am Coll Cardiol"},{"key":"2102_CR49","doi-asserted-by":"publisher","unstructured":"Cho MS, Yun JE, Park JJ, et al. Outcomes After Use of Standard- and Low-Dose Non-Vitamin K Oral Anticoagulants in Asian Patients With Atrial Fibrillation. Stroke. 2018: doi:https:\/\/doi.org\/10.1161\/strokeaha.118.023093:Strokeaha118023093. https:\/\/doi.org\/10.1161\/strokeaha.118.023093.","DOI":"10.1161\/strokeaha.118.023093:Strokeaha118023093 10.1161\/strokeaha.118.023093"},{"key":"2102_CR50","doi-asserted-by":"publisher","first-page":"6690","DOI":"10.1038\/s41598-019-43224-4","volume":"9","author":"SR Lee","year":"2019","unstructured":"Lee SR, Choi EK, Han KD, et al. Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation. Sci Rep. 2019;9:6690. https:\/\/doi.org\/10.1038\/s41598-019-43224-4.","journal-title":"Sci Rep"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02102-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02102-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02102-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T19:09:07Z","timestamp":1656443347000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02102-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["2102"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02102-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"assertion":[{"value":"15 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}